Vimian Group AB (publ) (VIMGF)
USD 3.62
(0.0%)
USD 3.62
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 69.18 Million EUR | 15.84% |
| 2022 | 39.91 Million USD | 32.6% |
| 2021 | 40.29 Million USD | 107.46% |
| 2020 | 29.84 Million USD | 324.78% |
| 2019 | 2.03 Million USD | 404.83% |
| 2018 | -437.64 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 18.41 Million USD | -18.93% |
| 2024 Q2 | 29.89 Million USD | 5.41% |
| 2024 Q1 | 21.55 Million EUR | 152.54% |
| 2023 FY | - USD | 15.84% |
| 2023 Q2 | 25.21 Million USD | -11.82% |
| 2023 Q1 | 28.6 Million USD | 38.88% |
| 2023 Q3 | 21.5 Million USD | -14.74% |
| 2023 Q4 | 14.02 Million USD | -34.79% |
| 2022 Q3 | 15.16 Million USD | -23.0% |
| 2022 FY | - USD | 32.6% |
| 2022 Q4 | 20.59 Million USD | 35.84% |
| 2022 Q2 | 19.68 Million EUR | -19.09% |
| 2022 Q1 | 24.33 Million EUR | 115.21% |
| 2021 FY | - USD | 107.46% |
| 2021 Q3 | 11.49 Million EUR | -23.05% |
| 2021 Q4 | 11.3 Million EUR | -1.67% |
| 2021 Q2 | 14.94 Million EUR | -16.51% |
| 2021 Q1 | 17.9 Million EUR | -76.19% |
| 2020 Q4 | 75.17 Million EUR | 1281.84% |
| 2020 FY | - USD | 324.78% |
| 2020 Q2 | -279 Thousand EUR | -118.61% |
| 2020 Q1 | 1.49 Million EUR | 0.0% |
| 2020 Q3 | 5.44 Million EUR | 2049.82% |
| 2019 FY | - USD | 404.83% |
| 2018 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | 6048.925% |
| Arrayit Corporation | -3.07 Million USD | 2348.127% |
| Atlantic International Corp. | -5.38 Million USD | 1383.704% |
| Biocept, Inc. | -30.24 Million USD | 328.782% |
| Bioqual, Inc. | 3.03 Million USD | -2181.68% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | 9234.973% |
| DermTech, Inc. | -97.89 Million USD | 170.675% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 97.626% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 441.787% |
| iMD Companies, Inc. | -154.65 Thousand USD | 44834.545% |
| IDenta Corp. | 71.58 Thousand USD | -96546.039% |
| Interpace Biosciences, Inc. | 3.83 Million USD | -1703.127% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | -178721.401% |
| InVitro International | 6680.00 USD | -1035618.563% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 1372.737% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | 570282.957% |
| Medical Imaging Corp. | -896.74 Thousand USD | 7815.263% |
| NovelStem International Corp. | -3.78 Million USD | 1927.514% |
| Optigenex Inc. | -1.18 Million USD | 5929.999% |
| PharmChem, Inc. | 1.05 Million USD | -6465.32% |
| Proteome Sciences plc | -1.13 Million USD | 6184.96% |
| Response Genetics, Inc | -19.66 Million USD | 451.805% |
| Rennova Health, Inc. | -234.81 Thousand USD | 29564.046% |
| RushNet, Inc. | -614.85 Thousand USD | 11352.464% |
| ScreenPro Security Inc. | -3.43 Million USD | 2114.214% |
| Stella Diagnostics Inc. | -5.7 Million USD | 1312.209% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 773.662% |
| Todos Medical Ltd. | -9.39 Million USD | 836.491% |